COMBINE 4 was a 40-week, open-label, treat-to-target phase 3b trial across 97 sites in nine countries. It randomised 485 insulin-naive adults with type 2 diabetes and HbA1c of 8.0% or above on oral drugs to either IcoSema, a once-weekly combination of basal insulin icodec and semaglutide, or once-daily insulin glargine U100. Median age was 58, and baseline HbA1c was around 9.5% in both arms. Both arms were titrated to the same fasting glucose target of 3.9-5.0 mmol/L (70-90 mg/dL).
At 40 weeks HbA1c fell by 3.32 percentage points with IcoSema against 2.44 with glargine, a difference of 0.88 percentage points (95% CI -1.12 to -0.63). Weight fell slightly on IcoSema and rose by 3.81 kg on glargine, a 4.61 kg gap. Clinically significant or severe hypoglycaemia ran at 0.29 versus 0.59 episodes per person-year, a rate ratio of 0.56 (95% CI 0.32 to 0.97). Gastrointestinal side effects were the commonest problem on the combination.
This matters because the usual trade for starting basal insulin is better glucose bought with weight gain and more hypoglycaemia. Here all three moved the right way at once, and the injection burden dropped from 365 to 52 a year. For Indian practice, where insulin initiation is often delayed by fear of hypoglycaemia and of weight gain, and where a weekly injection is easier to supervise in a family setting, that combination of advantages is the point. The caveats are real: the trial was open-label, ran only 40 weeks, and enrolled people starting from a high HbA1c, so the size of the gap may narrow in less uncontrolled patients. IcoSema is not yet available in India, so today this changes what you plan for, not what you prescribe.
- Identify the insulin-naive patients in your clinic on maximal oral therapy with HbA1c above 8% - they are the population this trial addresses
- Before calling oral therapy failed, confirm adherence, dosing and whether a GLP-1 receptor agonist has actually been tried
- Record baseline weight and a hypoglycaemia history at insulin initiation so the trade-off can be judged later
- Warn about nausea and reduced appetite in the first weeks of any semaglutide-containing regimen, and plan the titration around it
- Do not stop metformin or an SGLT2 inhibitor when adding a weekly basal combination unless there is a separate reason
The statistics, in plain English
The confidence interval for the HbA1c difference runs from -1.12 to -0.63 percentage points and never comes near zero, so the direction of the result is not in doubt; the uncertainty is only about whether the true benefit is nearer half a point or over one point. The hypoglycaemia rate ratio of 0.56 has an upper limit of 0.97, which only just clears 1.0 - the reduction is statistically real but the interval is wide enough that the true reduction could be anywhere from a two-thirds cut to almost nothing. Treat the hypoglycaemia finding as supportive rather than definitive. Note also that a treat-to-target design forces both arms towards the same fasting glucose, so the HbA1c advantage largely reflects the semaglutide component acting after meals, not better basal insulin.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free